《早老性痴呆药物研究进展》由会员分享，可在线阅读，更多相关《早老性痴呆药物研究进展（26页珍藏版）》请在金锄头文库上搜索。
1、早老性痴呆药物研究进展Stillwatersrundeep.流静水深流静水深,人静心深人静心深Wherethereislife,thereishope。有生命必有希望。有生命必有希望ContentsCurrent situation of AD1What are big companies doing 2Trends3Perspective42024/7/3121 Current situation of ADvPopulation：37 million vCauses：too sophisticatedvMarket drugs：Tarcrine，Donepezil，Rivastigmine
2、，Galanthamine，Huperzine，MemantinevSome social activities may correlate with AD，but cannot delay the progress of AD2024/7/313Nature Reviews.2010.7:387-3982024/7/3142 What are big companies doingvA big cake attracts a lot of big companies，attention，such as Pfizer，Elan，Merk，Novartis and so on2024/7/315
3、BMC Medicine 2009, 7:7 2024/7/316TramiprosatevALZHEMED（Neurochem Inc.） vThe Phase III trial did not show a beneficial effect on cognition or function，so the development program has been discontinued 2024/7/317Vaccines and antibodiesvAN-1792（Elan）the first-generation amyloid vaccine，Phase II trial wa
4、s discontinued owing to the development of aseptic meningoencephalitis in 6% of the patientsvACC-001（Elan）prevent the induction of a toxic cellular immune response，in a Phase II clinical trialvBapineuzumab (Elan/Wyeth) ：Phase III，monoclonal antibodiesvImmunoglobulin IgIV：Phase III，polyclonal antibod
5、ies2024/7/3182024/7/319RAGE InhibitorvAmyloid is known to bind to receptors for advanced glycated endproducts (RAGE) on the surface of cells and at the blood-brain barrier； this binding may contribute to inflammation and neuronal death.vPF-04494700 ：an orally bioavailable antagonist of RAGE，Phase II
6、 2024/7/3110-secretase inhibitorsvTarenflurbil：the enantiomer of the non-steroidal anti-inflammatory drug flurbiprofen，modulates the activity of -secretase，failed in Phase III vSemagacestat：reduction of amyloid peptide generation in blood and cerebrospinal fluid of patients with AD treated with tole
7、rable doses， in Phase III2024/7/3111Tau aggregation inhibitorvRember（Methylene blue）：a widely used histology dye, has been shown to interfere with tau aggregation.v Entering Phase III2024/7/31122024/7/3113Microtubule stabilizervNAP (AL-108)：derived from a natural neurotrophic protein, can be deliver
8、ed to the central nervous system via intranasal administration.vmarkedly reduces tau phosphorylation, and preliminary human studies have been encouraging.Now it is in Phase II trial.2024/7/3114Dimebon-Pfizerv Phase III trial(Dimebon and Donepezil): failed，but Pfizer now is launching another Phase II
9、I trial about dimebon with other AD drugs.2024/7/3115vPhase III trials of Ginkgo biloba, NSAIDs, phenserine, statins, tarenflurbil, tramiprosate, and xaliproden have been completed, none of them demonstrating adequate efficacy.vPhase II trials of dimebon, huperzine A, intravenous immunoglobulin, and
10、 methylthioninium chloride were reported at 2008. vNineteen compounds are currently in Phase II trials, and 3 compounds (AN1792, lecozotan SR, and SGS742) failed at this stage of development.2024/7/31163 TrendsvMultitarget Anti-Alzheimer AgentsvAD modelvfurther explore the causesvcoalition and coope
11、ration2024/7/3117Multitarget Anti-Alzheimer AgentsNovel Tacrine-8-Hydroxyquinoline Hybrids as Multifunctional Agents for the Treatment of Alzheimers Disease, with Neuroprotective, Cholinergic, Antioxidant, and Copper-Complexing Properties2024/7/31182024/7/3119Bivalent -Carbolines as Potential Multit
12、arget Anti-Alzheimer Agents2024/7/3120AD modelvA platform to perform pharmacological evaluation of animal models of Alzheimers diseasevIn the future drug candidates may be directly used to animal models of Alzheimers disease2024/7/3121Further explore the causesThe brain of AD patient likes a labyrin
13、th 2024/7/3122CooperationvWhile each of us is running into a stone wall with Alzheimers ，what will we do next？vAllow researchers to study a larger pool of patients will help us see how the disease progresses, identify subgroups, and hopefully develop more sophisticated computer models that could sav
14、e time and money developing drugs.2024/7/31234 PerspectivevWhile it is not possible to predict the success of any individual program, one or more are likely to prove effective.vDespite disappointing results from recently completed Phase III trials of several novel compounds, the extent and breadth o
15、f activity at all phases of clinical development suggest that new pharmacotherapeutic options for the treatment of AD will become available within the next decade. vIt seems reasonable to predict that in the not-too-distant future, a synergistic combination of agents will have the capacity to alter
16、the neurodegenerative cascade and reduce the global impact of this devastating disease.2024/7/3124Reference1 Michael S Rafii and Paul S Aisen.Recent developments in Alzheimers disease therapeutics.BMC Medicine 2009, 7:7 ,1741-7-15.2 Yvonne Rook.Bivalent -Carbolines as Potential Multitarget Anti-Alzh
17、eimer Agents.J.Med.C.XXXX,Vol.XXX,NO.XX3MaraIsabelFernandez-Bachiller.NovelTacrine-8-HydroxyquinolineHybrids as Multifunctional Agents for the Treatment of Alzheimers Disease, with Neuroprotective, Cholinergic, Antioxidant, and Copper-Complexing Properties.J.Med.C.XXXX,XXX,000-000.4 Raymond T. Bartu
18、s & Reginald L. Dean III.Pharmaceutical treatment for cognitive deficits in Alzheimers disease and other neurodegenerative conditions:exploring new territory using traditional tools and established maps.Psychopharmacology (2009) 202:1536.5 Marwan N. Sabbagh.Drug Development for Alzheimers Disease: Where Are We Now and Where Are We Headed?.The American Journal of Geriatric Pharmacotherapy 2009,7(3):167-185.6 Martin Citron.Alzheimers disease: strategies for disease modification.Nature Reviews.2010.7:387-398 2024/7/3126
